Penn Medicine Provider
Pathology and Laboratory Medicine
Douglas B. Cines, MD
Sees patients age 18 and up
Penn Blood Disorders Center
Make an appointmentCall 215-615-6555

About me

  • Director, Coagulation Laboratory
  • Professor of Pathology and Laboratory Medicine
  • Professor of Pathology and Laboratory Medicine in Medicine (Hematology-Oncology)

My areas of clinical expertise include coagulation and immune hematological disorders.

Education and training

  • Medical School: New York University School of Medicine
  • Residency: University of North Carolina Hospitals
  • Fellowship: Hospital of the University of Pennsylvania

Insurance accepted

My Locations

Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Cines is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Sarkar A, Yadav SK, Field CO, Gollomp K, McCrae KM, Ortel T, Gruel Y, Rollen J, Arepally GM, Rauova L, Cines DB, Poncz M. Anti-phospholipid syndrome (APS) antibody (Ab)-induced thrombosis can be blocked by platelet factor 4 (PF4)-directed Abs: A novel therapeutic for APS? , ASH: 2024

Myoung S, Francis SJ, Chen J, Lee G, Rauova L, Poncz M, Cines DB, Kuchibhatla M, Khandelwal S, Arepally GM. Complement Activation as a biomarker for platelet activating HIT antibodies. ASH 2024. , ASH: 2024

Field CO, Sarkar A, Bdeir Kh, McRae KR, Ortel TL, Kowalska MA, Rauova L, Cines DB, Gollomp K, Poncz M. Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder. , ASH: 2024

Rauova L, Oberg J, Gilbert S, Cines DB, Poncz M. A murine model of vaccine-induced immune thrombotic thrombocytopenia (VITT) leads to anti-NAP2 and anti-PF4 antibodies and may involve TLR9 activation. , ISTH: 2024

Ngo ATP, Skidmore A, Yarovoi I, Sarkar A, Levine ND, Bochenek V, Zhao G, Rauova L, Kowalska MA, Eckart K, Mangalmurti NS, Rux A, Cines DB, Poncz M, Gollomp K. Platelet factor 4 limits neutrophil extracellular trap- and cell-free DNA-induced thrombogenicity and endothelial injury. , JCI-Insight., 8(22): 2023

Bussel JM, Hou M, Cines DB. Management of primary ITP in pregnancy. , New Eng J Med., 389(6): 2023,540

Sarkar A, Khandelwal S, Koma G, Kim H, Gruel Y, Rollin J, Passam FH, Wool GD, Arepally GM, Cines DB, Rauova L, Poncz M. Prevention of thrombocytopenia and thrombosis in HIT using deglycosylated KKO: a novel therapeutic? , Blood Adv: 2023

Cines DB, Greinacher A. Vaccine-induced immune thrombotic thrombocytopenia , Blood, 141: 2023,1659-1665

Cai Z, Bdeir K, Yarovoi SV, Rauova L, Arepally GM, Khandelwal S, Rollin J, Gruel Y, Zaitsev S, Poncz M, Greene MI, Cines DB. Modulation of ultralarge immune complexes in heparin-induced thrombocytopenia , J Thromb Haemost: 2023

Rauova L, Oberg J, Field C, Levine N, Arepally HM, Cines DB, Cohen T, Poncz M ChadOx exposure-induced neutrophil-activating peptide 2 (NAP2) antibodies: Murine-based insights into the pathgenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT). , ISTH: 2023

View all publications